Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine



Status:Recruiting
Conditions:Diabetes, Diabetes
Therapuetic Areas:Endocrinology
Healthy:No
Age Range:18 - Any
Updated:3/16/2019
Start Date:February 14, 2019
End Date:December 2019
Contact:Trial Transparency email recommended (Toll free number for US & Canada)
Email:Contact-US@sanofi.com
Phone:800-633-1610

Use our guide to learn which trials are right for you!

Randomized, Open Label, Parallel-group Study Comparing the Pharmacokinetics and Immunogenicity of Alternating Use of SAR341402 and NovoLog® Versus Continuous Use of NovoLog in Participants With Type 1 Diabetes Mellitus Also Using Insulin Glargine

Primary Objective:

To demonstrate similarity in pharmacokinetics (PK) of SAR341402 and NovoLog after 4x4-week
periods of alternating administration of SAR341402 and NovoLog compared to 16-week continuous
use of NovoLog in participants with Type 1 diabetes mellitus also using insulin glargine.

Secondary Objectives:

- To compare the effects of alternating administration of SAR341402 and NovoLog with
continuous use of NovoLog on immunogenicity.

- To evaluate the safety of alternating administration of SAR341402 and NovoLog versus
continuous use of NovoLog.

- To compare other PK parameters between the two treatment arms (alternating
administration of SAR341402 and NovoLog and continuous use of NovoLog).

The study duration per participant is approximatively 18 weeks and 1 day including an up to
2-week screening period, a 16-week treatment period and 1-day post-treatment follow-up
period.

Inclusion criteria:

- Participants with type 1 diabetes mellitus.

- Participants on continuous insulin treatment for at least 12 months prior to
screening.

- Participants on a multiple (≥3) daily injection insulin regimen using NovoLog as
mealtime insulin and insulin glargine (100 U/mL) as basal insulin for at least 3
months prior to screening.

- Glycated hemoglobin (HbA1c) below 10% (85.79 mmol/mol) (inclusive) at screening.

- Body mass index (BMI) ≤35 kg/m² at screening.

Exclusion criteria:

- Pancreatectomy and/or islet cell transplantation.

- Clinically significant laboratory findings, as defined by the protocol.

- Known presence of factors that interfere with the HbA1c measurement.

- History of severe hypoglycemia requiring emergency room admission or hospitalization
within 3 months prior to screening.

- Hospitalization for recurrent diabetic ketoacidosis within 3 months prior to
screening.

- Retinopathy or maculopathy with one of the following treatments, either recent (within
3 months of screening) or planned: intravitreal injections or laser or vitrectomy
surgery.

- Use of glucose lowering treatments other than the multiple dose injections (MDI) and
basal insulin regimen (including use of insulin pump therapy), within 3 months prior
to screening.

- Participants having received systemic glucocorticoids (topical, nasal spray, inhaled
or intra-articular applications are allowed) for one week or more within 3 months
prior to screening.

- Participants having received immunosuppressive agents within 6 months prior to
screening.

The above information is not intended to contain all considerations relevant to a patient's
potential participation in a clinical trial.
We found this trial at
7
sites
?
mi
from
Flint, MI
Click here to add this to my saved trials
?
mi
from
Chattanooga, TN
Click here to add this to my saved trials
?
mi
from
Lexington, KY
Click here to add this to my saved trials
?
mi
from
Mesquite, TX
Click here to add this to my saved trials
?
mi
from
Rockville, MD
Click here to add this to my saved trials
?
mi
from
Temecula, CA
Click here to add this to my saved trials
?
mi
from
Ventura, CA
Click here to add this to my saved trials